Review Reports
- Juan Gao 1,2,
- Jieyi Long 1,3 and
- Bin Yang 1,*
- et al.
Reviewer 1: Jacek W. Morzycki Reviewer 2: Anonymous
Round 1
Reviewer 1 Report
Comments and Suggestions for Authors
The manuscript submitted by Chinese chemists describes products of large-scale fermentation with the fungus Aspergillus sclerotiorum SCSIO 41031, carried out under three different conditions. All isolated compounds (a total of 22; 3 new, 19 known) were identified using various spectroscopic techniques and subjected to biological activity tests. Two of these compounds showed significant cytotoxicity against four cancer cell lines. I recommend the manuscript for publication subject to minor revisions.
Specific comments and suggested changes:
- Abstract, line 17: ‘Seven culture conditions were tested’ – this information is not provided in the main text. The abstract should not contain new information.
- Abstract, lines 22/23: ‘1.95-6.35 µM’; ‘50.02 µM’ – IC50 values should be provided in the main text, not just in the abstract.
- Page 2 , lines 78/79: The name of compound 6 is not correct; use rather ‘sclerin diacid monoester (6)’.
- Page 2, last line: ‘phenylacetic acid (19)’, but compound 19 is neither phenylacetic acid nor its derivative.
- Page 3, Figure 1: What is the substituent at C-6 in compound 4? Neither the structure of this compound nor its name is correct.
- Page 3, Figure 1: Draw both compounds, 12 and 13, in the same way. Are these compounds in equilibrium in the solution via an intramolecular transesterification? If so, they should exhibit the same cytotoxicity.
- Page 3, Figure 1: Draw both compounds, 20 and 21, in the same way, i.e. with the aldehyde carbonyl group on the right side.
- Page 4, line 115; also page 8, line 260; also page 9, line 270: ‘… named 6,6’-diacetyl-…1,1’-phenylether’. The name is incorrect – compound 1 is a derivative of dibenzyl ether, not diphenyl ether.
- Page 4, Figure 2: Could you please draw an ORTEP for the entire compound 1?
- Page 5, line 125: I suggest to replace ‘an ester derivative …’ with ‘an acetyl derivative …’.
- Page 5, last paragraph: consider showing the structure of Pestalpolyol B.
- Page 6, Table 3: correct the alignment in the top row (gCOSY).
- Page 6, Figure 4: The NOESY correlations of compound 17 are unclear.
- Page 6, Bioassays: There is no detailed information regarding the biological activity of the compounds studied. Consider presenting the results of cytotoxicity tests in a table. Selected results are mentioned only in the Abstract and Conclusions. Please include them in the main text on page 6 or 12.
- Page 10, Conclusions, line 315: It seems to me that 'even fermentation conditions' should be replaced with 'Seven fermentation conditions'.
Author Response
- Comment:Abstract, line 17: ‘Seven culture conditions were tested’ – this information is not provided in the main text. The abstract should not contain new information.
Response: We fully understand your point that the abstract should not contain new information not presented in the main text. Therefore, we have revised this sentence to avoid mentioning the "testing of seven culture conditions" in the abstract, which was not detailed in the main text.
- Comment:Abstract, lines 22/23: ‘1.95-6.35 µM’; ‘50.02 µM’ – IC50 values should be provided in the main text, not just in the abstract.
Response: We have already removed the relevant content from the abstract.
- Comment:Page 2, lines 78/79: The name of compound 6 is not correct; use rather ‘sclerin diacid monoester (6)’.
Response: We have corrected the name of Compound 6 to "sclerin diacid monoester(6)".
- Comment:Page 2, last line: ‘phenylacetic acid (19)’, but compound 19 is neither phenylacetic acid nor its derivative.
Response: After verification, we have accurately modified the name of Compound 19. It is neither phenylacetic acid nor its derivative, and compound 19 was identified as 3-phenyllactic acid.
- Comment:Page 3, Figure 1: What is the substituent at C-6 in compound 4? Neither the structure of this compound nor its name is correct.
Response: For Compound 4, we have clarified the substituent at the C-6 position and made correct corrections to both its structure and name.
- Comment:Page 3, Figure 1: Draw both compounds, 12 and 13, in the same way. Are these compounds in equilibrium in the solution via an intramolecular transesterification? If so, they should exhibit the same cytotoxicity.
Response: We have followed your suggestion to draw compounds 12 and 13 in the same way. Compounds 12 and 13 exhibit different activities against the same cancer cell line, suggesting that they may not reach equilibrium in solution via an intramolecular transesterification reaction.
- Comment:Page 3, Figure 1: Draw both compounds, 20 and 21, in the same way, i.e. with the aldehyde carbonyl group on the right side.
Response: We have drawn compounds 20 and 21 with the aldehyde carbonyl group on the right side as required.
- Comment:Page 4, line 115; also page 8, line 260; also page 9, line 270: ‘… named 6,6’-diacetyl-…1,1’-phenylether’. The name is incorrect – compound 1 is a derivative of dibenzyl ether, not diphenyl ether.
Response: We have corrected the name, clarifying that compound 1 is a derivative of dibenzyl ether, not diphenyl ether. Compound 1 was named 6,6'-diacetyl-1,1'-dihydroxy-3,3'-dimethoxydibenzyl ether.
- Comment:Page 4, Figure 2: Could you please draw an ORTEP for the entire compound 1?
Response: Compound 1 is a dimer; during single-crystal cultivation, the conditions of time or temperature may have led to the isolation of a monomeric structure in the measured crystal.
- Comment:Page 5, line 125: I suggest to replace ‘an ester derivative …’ with ‘an acetyl derivative …’.
Response: We have replaced "an ester derivative..." with "an acetyl derivative...".
- Comment:Page 5, last paragraph: consider showing the structure of Pestalpolyol B.
Response: We have presented the structure of Pestalpolyol B to help readers better understand the relevant content.
- Comment:Page 6, Table 3: correct the alignment in the top row (gCOSY).
Response: We have corrected the alignment problem in the top row (gCOSY) of Table 3.
- Comment:Page 6, Figure 4: The NOESY correlations of compound 17 are unclear.
Response: We have redrawn Figure 4 to clearly present the NOESY correlations of compound 17.
- Comment:Page 6, Bioassays: There is no detailed information regarding the biological activity of the compounds studied. Consider presenting the results of cytotoxicity tests in a table. Selected results are mentioned only in the Abstract and Conclusions. Please include them in the main text on page 6 or 12.
Response: We apologize for the lack of clarity in our earlier draft, which may have caused confusion. We sincerely thank the reviewer for the thoughtful suggestion to improve the presentation of the bioactivity data. The cytotoxicity data for compounds 12 and 13 were originally reported in our previously published studies. It is worth noting that the same compound can sometimes be isolated from different microbial strains. In our ongoing screening workflow, we aim to avoid redundant testing of the same compound to improve efficiency and reduce resource use. As such, we did not conduct new cytotoxicity assays for these compounds during the current study. In response to the reviewer’s comment, we have revised the main text to clearly indicate that the data for compounds 12 and 13 are supported by previously reported literature, with appropriate citations now included. We appreciate the reviewer’s understanding and hope that this clarification addresses the concern while maintaining the integrity of the data.
- Comment:Page 10, Conclusions, line 315: It seems to me that 'even fermentation conditions' should be replaced with 'Seven fermentation conditions'.
Response: We have revised the sentence, and the updated version is: "Large-scale fermentation was performed using three optimized culture media."
Reviewer 2 Report
Comments and Suggestions for Authors
The submitted manuscript “Chemical Diversity and Antitumor Metabolites from SoftCoral-Derived Fungus Aspergillus sclerotiorum SCSIO 41031 via OSMAC Strategy” by Liu and Yang described the application of the OSMAC strategy to a marine-derived fungus, leading to the discovery of new compounds (1, 17 and 20) together with 19 known compounds. Compounds 12 and 13 showed cytotoxicity against four tumor cell lines (K562, Molt-4, Hela, HL60) with IC50 values of 1.95–6.35 μM. The work is within the scope of Marine Drugs.
However, several revisions and corrections are necessary to improve its clarity and scientific rigor
1. The name of compound 1 is not corect. The methoxy at 3 and 3’ position but the name is hydroxy group. Correct the name in the Material and Methods section, don’t use : "6:6'- Diacetyl- 2:2'dihydroxymethy- 3:3'- dihydroxy- 1- Phenylether"
2. Line 141-145: Re-wrire this part. The assignment of relative configuration as "2E, 4S, 5S..." for a compound with multiple double bonds is confusing. The "E" refers to double bond geometry, while "R/S" refers to chiral centers.
3. R, S in intalic
4. Line 323-331: Move this discussion about the lack of peptide compounds from the alternative media to the Results and Discussion section (Section 2.1). Explain the hypothesis (hoped for more peptides) and the actual outcome. Discuss why this might be (e.g., salinity, nutrients, time).
5. Give more information about cancer cell lines (which kinds of cancer cell lines HeLa, HL-60, K562, MOLT-4, ACHN, 786-O, OS-RC-2, HONE1, and HONE1-EBV). Provide the tables summarizing the bioactivity results for all tested compounds and cell lines/assays. Discuss the significance of the findings, comparing them to known standards.
6. Page 10, line 315: Correct even fermentations as Seven fermentations
7. Rewrite the Conclusion to be a concise summary of the paper's main findings: the successful application of OSMAC, the number and types of compounds isolated (highlighting the 3 new ones), and the most significant bioactivity results (e.g., potent cytotoxicity of 12 and 13).
8. Cite the Figure in the SI in the main text of the manuscript.
9. Correct FigureS 20: NOESY not HSQC
References 13 and 16 are duplicated
Author Response
- Comment:The name of compound 1 is not corect. The methoxy at 3 and 3’ position but the name is hydroxy group. Correct the name in the Material and Methods section, don’t use : "6:6'- Diacetyl- 2:2'dihydroxymethy- 3:3'- dihydroxy- 1- Phenylether"
Response: Based on the positional information of the methyl and hydroxyl groups you provided, we have correctly revised the name of compound 1 to: 6,6'-Diacetyl-1,1'-dihydroxy-3,3'-dimethoxydibenzyl ether.
- Comment:Line 141-145: Re-wrire this part. The assignment of relative configuration as "2E, 4S, 5S..." for a compound with multiple double bonds is confusing. The "E" refers to double bond geometry, while "R/S" refers to chiral centers.
Response: We have rewritten the description of the relative configuration assignment for compound 1 in lines 141–145. We clarified the notation “2E,4S,5S…” for compounds containing multiple double bonds by separately specifying the geometry of the double bonds (E/Z) and the configurations of the stereocenters (R/S).
- Comment:R, S in italic.
Response: We have changed R and S to italic format.
- Comment:Line 323-331: Move this discussion about the lack of peptide compounds from the alternative media to the Results and Discussion section (Section 2.1). Explain the hypothesis (hoped for more peptides) and the actual outcome. Discuss why this might be (e.g., salinity, nutrients, time).
Response: We have moved the discussion about the lack of peptide compounds in alternative media from Lines 323 - 331 to the "Results and Discussion" section (Section 2.1).
- Comment:Give more information about cancer cell lines (which kinds of cancer cell lines HeLa, HL-60, K562, MOLT-4, ACHN, 786-O, OS-RC-2, HONE1, and HONE1-EBV). Provide the tables summarizing the bioactivity results for all tested compounds and cell lines/assays. Discuss the significance of the findings, comparing them to known standards.
Response: We apologize for the lack of clarity in our earlier draft, which may have caused confusion. We sincerely thank the reviewer for the thoughtful suggestion to improve the presentation of the bioactivity data. The cytotoxicity data for compounds 12 and 13 were originally reported in our previously published studies. It is worth noting that the same compound can sometimes be isolated from different microbial strains. In our ongoing screening workflow, we aim to avoid redundant testing of the same compound to improve efficiency and reduce resource use. As such, we did not conduct new cytotoxicity assays for these compounds during the current study. In response to the reviewer’s comment, we have revised the main text to clearly indicate that the data for compounds 12 and 13 are supported by previously reported literature, with appropriate citations now included. We appreciate the reviewer’s understanding and hope that this clarification addresses the concern while maintaining the integrity of the data.
- Comment:Page 10, line 315: Correct even fermentations as Seven fermentations.
Response: We have revised the sentence, and the updated version is: "Large-scale fermentation was performed using three optimized culture media."
- Comment:Rewrite the Conclusion to be a concise summary of the paper's main findings: the successful application of OSMAC, the number and types of compounds isolated (highlighting the 3 new ones), and the most significant bioactivity results (e.g., potent cytotoxicity of 12 and 13).
Response: We have rewritten the conclusion to be a concise summary of the paper's main findings, including the successful application of OSMAC, the number and types of compounds isolated (highlighting the 3 new ones), and the most significant bioactivity results.
- Comment:Cite the Figure in the SI in the main text of the manuscript.
Response: We have cited the figure in the Supplementary Information (SI) in the main text of the manuscript.
- Comment:Correct FigureS 20: NOESY not HSQC.
Response: We have corrected Figure S20, changing the label from HSQC to NOESY.
- Comment:References 13 and 16 are duplicated.
Response: We have correctly cited reference 16.
Round 2
Reviewer 2 Report
Comments and Suggestions for Authors
The authors have modified their manuscript but some points the authors did not correct.
Line 141-145: This sentence is wrong "Large coupling constants (7.9 Hz) for H-4/H-5, H-8/H-9, and H-12/H-13 indicated the trans (E) geometry of these double bonds".
The double bonds locate at C-2/C-3; C-6/C-7, C-10/C-11 and C-14/C-15, how can the Large coupling constants (7.9 Hz) for H-4/H-5, H-8/H-9, and H-12/H-13 can prove the trans (E) geometry ?
"NOESY experiments revealed through-space correlations between H-3/H-18, H-3/H-20, and H-3/H-22 with H-5, H-9, and H-13, respectively, consistent with these protons residing on the same face of the molecule" should be correct as H-3/H-18, H-7/H-20, and H-11/H-22 with H-5, H-9, and H-13.
The authors did not provide the table of biological activity of isolated compounds.
In addition, the manuscript has high ration of duplication (42%)
Therefore, the manuscript still need major revision.
Author Response
Dear Reviewer,
We sincerely appreciate your time and valuable feedback on our revised manuscript. We have carefully considered each of your comments and made the following revisions to address your concerns.
- Comment:Line 141-145: This sentence is wrong "Large coupling constants (7.9 Hz) for H-4/H-5, H-8/H-9, and H-12/H-13 indicated the trans (E) geometry of these double bonds".The double bonds locate at C-2/C-3; C-6/C-7, C-10/C-11 and C-14/C-15, how can the Large coupling constants (7.9 Hz) for H-4/H-5, H-8/H-9, and H-12/H-13 can prove the trans (E) geometry?
Response: You are absolutely right. The large vicinal coupling constants (9.2 Hz) actually reflect the trans (E) geometry of the double bonds at C-2/C-3, C-6/C-7, C-10/C-11, and C-14/C-15, as these values are consistent with the typical range for trans-configured olefinic protons. To avoid ambiguity, we have revised the text to explicitly state: The coupling constant of 7.9 Hz between the allylic protons H-4/H-5, H-8/H-9, and H-12/H-13 suggests a gauche-dominant conformation of the adjacent methylene groups. Large coupling constants (9.7 Hz, 9.2 Hz and 9.1 Hz) for H‑3/H‑4, H‑7/H‑8, and H‑11/H‑12 indicated trans (E) geometry of these double bonds.
- Comment:"NOESY experiments revealed through-space correlations between H-3/H-18, H-3/H-20, and H-3/H-22 with H-5, H-9, and H-13, respectively, consistent with these protons residing on the same face of the molecule" should be correct as H-3/H-18, H-7/H-20, and H-11/H-22 with H-5, H-9, and H-13.
Response: Thank you for pointing out this mistake. We have carefully re-examined the NOESY spectrum and confirmed that the correct through-space correlations.
- Comment:The authors did not provide the table of biological activity of isolated compounds.
Response: We acknowledge this omission. A new Table 4 (Cytotoxic of compounds 12, 13 and 22) has been added to the manuscript.
- Comment:In addition, the manuscript has high ration of duplication (42%).
Response: We apologize for the excessive text duplication. We have thoroughly reviewed the manuscript. Removed redundant phrases, repetitive descriptions of methods.
We thank you again for your constructive criticism, which has significantly strengthened the quality of our manuscript. Please let us know if further clarifications or revisions are needed.
Round 3
Reviewer 2 Report
Comments and Suggestions for Authors
The authors have corrected their manuscript based on the reviewer's suggestions.
The manuscript can be accepted for publication in Marine Drugs.
Author Response
Dear Reviewer,
Thank you very much for taking the time to review our manuscript and for your constructive and insightful comments.